Development of a multiple-antigen protein fusion vaccine candidate that confers protection against Bacillus anthracis and Yersinia pestis
JournalPLoS neglected tropical diseases
PublisherPublic Library of Science
MetadataShow full item record
AbstractBacillus anthracis and Yersinia pestis are zoonotic bacteria capable of causing severe and sometimes fatal infections in animals and humans. Although considered as diseases of antiquity in industrialized countries due to animal and public health improvements, they remain endemic in vast regions of the world disproportionally affecting the poor. These pathogens also remain a serious threat if deployed in biological warfare. A single vaccine capable of stimulating rapid protection against both pathogens would be an extremely advantageous public health tool. We produced multiple-antigen fusion proteins (MaF1 and MaF2) containing protective regions from B. anthracis protective antigen (PA) and lethal factor (LF), and from Y. pestis V antigen (LcrV) and fraction 1 (F1) capsule. The MaF2 sequence was also expressed from a plasmid construct (pDNA-MaF2). Immunogenicity and protective efficacy were investigated in mice following homologous and heterologous prime-boost immunization. Antibody responses were determined by ELISA and anthrax toxin neutralization assay. Vaccine efficacy was determined against lethal challenge with either anthrax toxin or Y. pestis. Both constructs elicited LcrV and LF-specific serum IgG, and MaF2 elicited toxin-neutralizing antibodies. Immunizations with MaF2 conferred 100% and 88% protection against Y. pestis and anthrax toxin, respectively. In contrast, pDNA-MaF2 conferred only 63% protection against Y. pestis and no protection against anthrax toxin challenge. pDNA-MaF2-prime MaF2-boost induced 75% protection against Y. pestis and 25% protection against anthrax toxin. Protection was increased by the molecular adjuvant CARDif. In conclusion, MaF2 is a promising multi-antigen vaccine candidate against anthrax and plague that warrants further investigation.
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85071788792&doi=10.1371%2fjournal.pntd.0007644&partnerID=40&md5=f8fb986bb0da3ffffbc32e46b7e35bfb; http://hdl.handle.net/10713/10857
- A Bacteriophage T4 Nanoparticle-Based Dual Vaccine against Anthrax and Plague.
- Authors: Tao P, Mahalingam M, Zhu J, Moayeri M, Sha J, Lawrence WS, Leppla SH, Chopra AK, Rao VB
- Issue date: 2018 Oct 16
- A Bivalent Anthrax-Plague Vaccine That Can Protect against Two Tier-1 Bioterror Pathogens, <i>Bacillus anthracis</i> and <i>Yersinia pestis</i>.
- Authors: Tao P, Mahalingam M, Zhu J, Moayeri M, Kirtley ML, Fitts EC, Andersson JA, Lawrence WS, Leppla SH, Chopra AK, Rao VB
- Issue date: 2017
- Electroporation of a multivalent DNA vaccine cocktail elicits a protective immune response against anthrax and plague.
- Authors: Albrecht MT, Livingston BD, Pesce JT, Bell MG, Hannaman D, Keane-Myers AM
- Issue date: 2012 Jul 6
- Involvement of CD8+ T cell-mediated immune responses in LcrV DNA vaccine induced protection against lethal Yersinia pestis challenge.
- Authors: Wang S, Goguen JD, Li F, Lu S
- Issue date: 2011 Sep 9
- Immunization of mice with YscF provides protection from Yersinia pestis infections.
- Authors: Matson JS, Durick KA, Bradley DS, Nilles ML
- Issue date: 2005 Jun 24